GenKyoTex announces positive post-hoc analysis of PBC Phase 2 trial

by Eclosion Team | Jul 25, 2019 | Uncategorized

Setanaxib (GKT831) achieved statistical significance (p=0.02) for primary endpoint with the 400mg BID versus placebo, after correction of nonnormal distribution (outliers) in 400mg OD In advanced patients, setanaxib 400mg BID achieved significant reductions in GGT...

The WHO recognizes NOX inhibitors as new therapeutic class and approves SETANAXIB for GKT831

by Eclosion Team | Jul 22, 2019 | Uncategorized

World Health Organization (WHO) recognized GKT831 as first representative of NOX inhibitor therapeutic class The recommended new stem “naxib” recognizes NOX inhibitors as a new therapeutic class The NOX inhibitor therapeutic class has significant potential in...

Genkyotex Announces FDA Approval of Phase 2 InvestigatorInitiated Trial with GKT831 in IPF

by Eclosion Team | Jul 17, 2019 | Uncategorized

Study expands potential clinical indications for lead compound Trial fully funded via a grant from the United States National Institutes of Health Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX...

GeNeuro: Frontiers in Genetics review supports role of hidden DNA viruses in neurological disorders

by Eclosion Team | Jul 11, 2019 | Uncategorized

Human Endogenous Retroviruses linked to MS, Type 1 diabetes, ALS, schizophrenia GeNeuro’s temelimab most advanced drug candidate targeting pathogenic HERV Geneva, Switzerland,  11 July 2019 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a...

GENKYOTEX’S GKT831 PREVENTS MULTIPLE COMPLICATIONS OF PORTAL HYPERTENSION IN PRECLINICAL MODEL

by Eclosion Team | Jul 1, 2019 | Uncategorized

DATA SUPPORTS THERAPEUTIC ROLE OF GKT831 IN ADVANCED LIVER FIBROSIS Results published in Clinics and Research in Hepatology and Gastroenterology Phase 3 trial being planned in primary biliary cholangitis Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX),...